Drug Trial Radar · NCT04806451
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Last checked: Nov 19, 2026Latest source record: Feb 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
103
Actual
Start
Jun 25, 2021
Primary completion
Mar 10, 2023
Study completion Aug 2027
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Mar 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric participants with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of open-label treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 14 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).
Conditions
- Congenital Adrenal Hyperplasia
Interventions
CrinecerfontDrug
CRF type 1 receptor antagonist
PlaceboDrug
Non-active dosage form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Serum Androstenedione at Week 4Time frame: Baseline, Week 4
Locations
46 sites in 10 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Birmingham, Alabama
Neurocrine Clinical Site
Los Angeles, California
Neurocrine Clinical Site
Orange, California
Neurocrine Clinical Site
San Diego, California
Neurocrine Clinical Site
San Francisco, California
Neurocrine Clinical Site
Aurora, Colorado
Neurocrine Clinical Site
Hartford, Connecticut
Neurocrine Clinical Site
Washington D.C., District of Columbia
Neurocrine Clinical Site
Atlanta, Georgia
Neurocrine Clinical Site
Indianapolis, Indiana
Neurocrine Clinical Site
Boston, Massachusetts
Neurocrine Clinical Site
Ann Arbor, Michigan
Neurocrine Clinical Site
Minneapolis, Minnesota
Neurocrine Clinical site
St Louis, Missouri
Neurocrine Clinical Site
New Hyde Park, New York
Neurocrine Clinical Site
New York, New York
Neurocrine Clinical Site
Oklahoma City, Oklahoma
Neurocrine Clinical Site
Tulsa, Oklahoma
Neurocrine Clinical Site
Philadelphia, Pennsylvania
Neurocrine Clinical Site
Pittsburgh, Pennsylvania
Neurocrine Clinical Site
Dallas, Texas
Neurocrine Clinical Site
Seattle, Washington
Neurocrine Clinical Site
Brussels, Belgium
Neurocrine Clinical Site
Ghent, Belgium
Neurocrine Clinical Site
Edmonton, Alberta, Canada
Neurocrine Clinical Site
Vancouver, British Columbia, Canada
Neurocrine Clinical Site
Montreal, Quebec, Canada
Neurocrine Clinical Site
Angers, France
Neurocrine Clinical Site
Bordeau, France
Neurocrine Clinical Site
Le Kremlin-Bicêtre, France
Neurocrine Clinical Site
Paris, France
Neurocrine Clinical Site
Paris, France
Neurocrine Clinical Site
Berlin, Germany
Neurocrine Clinical Site
Heidelberg, Germany
Neurocrine Clinical Site
Magdeburg, Germany
Neurocrine Clinical Site
Athens, Greece
Neurocrine Clinical Site
Athens, Greece
Neurocrine Clinical Site
Bologna, Italy
Neurocrine Clinical Site
Milan, Italy
Neurocrine Clinical Site
Naples, Italy
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.